BD completes latest trial for wearable injector

BD (Becton, Dickinson and Company), has announced the completion of a 50-subject human clinical trial with the BD Libertas Wearable Injector.

The injector is a subcutaneous drug delivery system, currently in development, that is designed to require no patient assembly and deliver biologics with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations.

The study was designed to evaluate the performance of the 5 mL BD Libertas device in human subjects, including tissue effects, skin reactivity and patient acceptance. The results are expected to be announced early 2020.

The study represents the most recent in a series of over 50 BD conducted pre-clinical and clinical studies intended to measure the performance of the BD Libertas Wearable Injector, demonstrate feasibility of 2-10 mL biologic injections into subcutaneous tissue and characterise tissue response to large volume injections in human and animal subjects.

Peter Nolan, worldwide president, BD Pharmaceutical Systems, said: “BD is committed to bringing value to our pharma partnerships, including providing them with independent BD sponsored and generated study data to accelerate combination product development. The recent study reflects BD’s continued investment in solutions to meet pharma’s needs by expanding the design space for biologics delivery.”